Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases

Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases

Abstract Background Dysregulated activation of the inflammasome is involved in various human diseases including acute cerebral ischemia, multiple sclerosis and sepsis. Though many inflammasome inhibitors targeting NOD-like receptor protein 3 (NLRP3) have been designed and developed, none of the inhi...

Full description

Bibliographic Details
Main Authors: Chen Chen, YuWei Zhou, XinPeng Ning, ShengLong Li, DongDong Xue, CaiLv Wei, Zhu Zhu, LongXiang Sheng, BingZheng Lu, Yuan Li, XiaoYuan Ye, YunZhao Fu, Chuan Bai, Wei Cai, YuXuan Ding, SuiZhen Lin, GuangMei Yan, YiJun Huang, Wei Yin
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Journal of Neuroinflammation
Subjects:
ASC inhibitors
Inflammasome
Lonidamine
Multiple sclerosis
Ischemic stroke
Sepsis
Online Access:https://doi.org/10.1186/s12974-022-02682-w

Internet

https://doi.org/10.1186/s12974-022-02682-w

Similar Items